Phase 1 N=7 Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis
Psoriasis
Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=123 A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Generalized Pustular Psoriasis
Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002
Phase 2 N=8 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
Generalized Pustular Psoriasis
Primary: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale — 75.0; 75.0 percentage of participants
Phase 3 N=12 Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Psoriasis
Primary: Number of Patients With Treatment Success at Week 16 Using Non-responder Imputation (Full Analysis Set) — 10; 2; 9; 1 Participants
Phase 3 N=10 Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
Generalized Pustular Psoriasis (GPP) · Adalimumab · Japanese
Primary: Proportion of Participants Achieving Clinical Response at Week 16 — 7 Participants
Phase 3 N=45 Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Generalized Pustular Psoriasis
Primary: Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) — 8; 8; 2 Participants
Phase 3 N=11 An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Generalized Pustular Psoriasis
Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) — 7 Participants
Phase 4 N=12 A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Generalized Pustular Psoriasis · Erythrodermic Psoriasis
Primary: Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS — 1; 0…
Phase 3 N=15 A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change
Phase 3 N=39 An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
Generalized Pustular Psoriasis
Primary: Occurrence of Treatment Emergent Adverse Events (AEs) — 18; 12 Participants
Phase 3 N=159 An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Primary: Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16 — -7.79; -15.08; -11.07 Units on a scale — p=<0.001
Phase 2 N=53 Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
Generalized Pustular Psoriasis
Primary: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1…
Phase 3 N=17 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Psoriasis
Primary: Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16 — 100; 100 percentage of participants
Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Palmoplantar Pustular Psoriasis
Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722
Phase 2 N=14 Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)
Pityriasis Rubra Pilaris
Primary: Mean Change From Baseline Psoriasis Area and Severity Index (PASI) at Week-24 After Treatment With Guselkumab. — 61.8 percent change from baseline PASI
Phase 2 N=33 Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis
Psoriasis
Primary: Change From Baseline in the Palmo-plantar Pustulosis Psoriasis Area and Severity Index (PPPASI) Score at the End of Treatment (EOT) (Week 24) or at the Last Assessment…
Phase 3 N=23 Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
Psoriasis
Primary: Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions. — 4 participants
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 3 N=289 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
Psoriasis
Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003
Phase 2 N=35 A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Log Transformed Ratio of Postbaseline Fresh Pustule Count at Day 28 to Baseline — 0.86; 0.53 Log transformed ratio — p=0.24
N/A N=11 Blue Light Phototherapy
Grover's Disease · Psoriasis Vulgaris
Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count
Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…
Phase 3 N=24 Safety and Efficacy of Infliximab in Palmoplantar Psoriasis
Palmoplantar Psoriasis
Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
Phase 2 N=59 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Palmoplantar Pustulosis
Primary: Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI) — -6.0; -6.1 score on a scale — p=0.944
Phase 2 N=4 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Pyoderma Gangrenosum
Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…
N/A N=8 308nm Excimer Laser for Treatment of Fingernail Psoriasis
Nail Psoriasis
Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale
Phase 2 N=90 A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
Palmoplantaris Pustulosis
Primary: Percentage of Participants Who Achieve a PPPASI-50 at Week 16 — 40.9; 78.3 Percentage of Partcipants — p=0.0003